Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.65 |
| ▸ | FNTB | P49356 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.50 |
| ▸ | SQLE | Q14534 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940703 | 1.00 | FNTA (0.65) | FNTAFNTBKMT2AALOX15MEN1 | |
| SCHEMBL15639480 | 0.98 | FNTA (0.68) | FNTAFNTBKMT2AALOX15MEN1 | |
| SCHEMBL11652143 | 0.91 | FNTA (0.59) | FNTAFNTBKMT2AALOX15MEN1 | |
| SCHEMBL30368947 | 0.89 | FNTA (0.62) | FNTAFNTBKMT2AALOX15MEN1 | |
| SCHEMBL30368929 | 0.89 | FNTA (0.62) | FNTAFNTBKMT2AALOX15MEN1 | |
| SCHEMBL29004811 | 0.89 | FNTA (0.62) | FNTAFNTBKMT2AALOX15MEN1 | |
| SCHEMBL28442015 | 0.88 | FNTA (0.56) | FNTAFNTBKMT2AALOX15MEN1 | |
| SCHEMBL1395164 | 0.86 | FNTA (0.73) | FNTAFNTBKMT2AALOX15MEN1 | |
| SCHEMBL14815528 | 0.86 | FNTA (0.58) | FNTAFNTBKMT2AALOX15MEN1 | |
| SCHEMBL8619861 | 0.85 | FNTA (0.77) | FNTAFNTBKMT2AALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445384-B1 | COMPOSITION FOR TREATING DIASTOLIC DYSFUNCTION | STICHTING VUMC (NL) | 2023-07-12 | — | — | EP | claimed |
| US-11504415-B2 | Treatment of heart failure with preserved ejection fraction | STICHTING VUMC (NL) | 2022-11-22 | — | — | US | claimed |
| EP-2259844-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | Vicus Therapeutics SPE 1, LLC (US) | 2010-12-15 | — | — | EP | claimed |
| WO-2009111648-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | VICUS THERAPEUTICS, LLC (US) | 2009-09-11 | — | — | WO | claimed |
| US-20080089950-A1 | Methods and compositions for modulating the immune system and uses thereof | CHEN LAN B | 2008-04-17 | — | — | US | claimed |
| EP-1563849-A2 | Methods and compositions for modulating the immune system and uses thereof | DANA-FARBER CANCER INSTITUTE (US) | 2005-08-17 | — | — | EP | claimed |
| EP-1455775-A2 | METHODS AND COMPOSITIONS FOR MODULATING THE IMMUNE SYSTEM AND USES THEREOF | DANA-FARBER CANCER INSTITUTE (US) | 2004-09-15 | — | — | EP | claimed |
| US-20040022869-A1 | Methods and compositions for modulating the immune system and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. | 2004-02-05 | — | — | US | claimed |
| WO-2003047524-A2 | METHODS AND COMPOSITIONS FOR MODULATING THE IMMUNE SYSTEM AND USES THEREOF | DANA-FARBER CANCER INSTITUTE (US) | 2003-06-12 | — | — | WO | claimed |
| JP-7215873-A | — | — | None | — | — | JP | disclosed |
| JP-7309710-A | — | — | None | — | — | JP | disclosed |
| US-12600969-B2 | Expression control using a regulatable intron | AskBio Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12576076-B2 | Use of HSP70 as a regulator of enzymatic activity | Zevra Denmark A/S (DK) | 2026-03-17 | — | — | US | disclosed |
| US-20250262152-A1 | DEVICES, SYSTEMS, KITS, AND METHODS FOR DRUG DELIVERY TO THE SPINAL CORD | OHIO STATE INNOVATION FOUNDATION | 2025-08-21 | — | — | US | disclosed |
| EP-1289489-A2 | TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE | PENTAPHARM Ltd. (CH) | 2003-03-12 | — | — | EP | disclosed |
| CN-1348434-A | Preparation of gamma, delta-unsaturated ketones by carroll reaction | BASF AG (DE) | 2002-05-08 | — | — | CN | disclosed |
| WO-2001091715-A2 | TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE | PENTAPHARM LTD. (CH) | 2001-12-06 | — | — | WO | disclosed |
| JP-H07309710-A | EXTERNAL BASE | EISAI CO LTD | 1995-11-28 | — | — | JP | disclosed |
| JP-H07215873-A | CARDIOTONIC | OTSUKA PHARMACEUT CO LTD | 1995-08-15 | — | — | JP | disclosed |
| US-4116955-A | META-CYCLOPHANE AND A TRANS-TERPENOID, SEPARATION OF ISOMERS | TEIJIN LIMITED (JP) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600969-B2 | Expression control using a regulatable intron | XBP1, ATF4, HSPA5 | FNTA 979/4885FNTB 628/4885KMT2A 4762/4885 |
| US-12576076-B2 | Use of HSP70 as a regulator of enzymatic activity | HSPB1, HSPA1B, HSPD1 | FNTA 2571/4885FNTB 693/4885KMT2A 4482/4885 |
| US-20080089950-A1 | Methods and compositions for modulating the immune system and uses thereof | ICOS, MALT1, LTA | FNTA 2402/4885FNTB 4778/4885KMT2A 1874/4885 |
| US-20040022869-A1 | Methods and compositions for modulating the immune system and uses thereof | ICOS, MALT1, LTA | FNTA 2402/4885FNTB 4778/4885KMT2A 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.